AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2119303 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of phenytoin (PHT)
Number of subjects: 58
Study 2119303 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of carbamazepine (CBZ)
Number of subjects: 58
Study 2119303 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of valproate (VPA)
Number of subjects: 58
Study 2119303 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued existing therapy)
Number of subjects: 58
Study 31926883 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-Sulfamethoxazole (TMP-SMZ) 160 mg/800 mg twice daily for 45 days followed by 1 dose every other day for 311 days
Number of subjects: 141
Study 31926883 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch tablet) every other day for 311 days
Number of subjects: 141
Study 31835508 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined resistance and aerobic exercise training program (3 times per week for 12 weeks)
Number of subjects: 20
Study 31835508 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained regular lifestyle)
Number of subjects: 20
Study 27859395 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid at a dosage of 10 mg/kg, administered 4-9 hours preoperatively
Number of subjects: 26
Study 27859395 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid at a dosage of 1 mg/kg
Number of subjects: 26
Study 27859395 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid at a dosage of 10 mg/kg, administered 3-14 hours preoperatively
Number of subjects: 26
Study 25886987 — intervention group
Group type: EXPERIMENTAL
Intervention: Videos of walking people
Number of subjects: 0
Study 25886987 — intervention group
Group type: COMPARATOR
Intervention: Videos of nature
Number of subjects: 0
Study 23906938 — intervention group
Group type: EXPERIMENTAL
Intervention: mTOR inhibitor everolimus (n=16)
Number of subjects: 36
Study 23906938 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin inhibitor and/or mycophenolate sodium (n=20)
Number of subjects: 36
Study 21244500 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% autologous bone (AB) to 50% anorganic bovine bone (ABB) ratio (Group 1)
Number of subjects: 28
Study 21244500 — intervention group
Group type: COMPARATOR
Intervention: 20% autologous bone (AB) to 80% anorganic bovine bone (ABB) ratio (Group 2)
Number of subjects: 28
Study 19728118 — intervention group
Group type: COMPARATOR
Intervention: Calcium and Vitamin D supplementation
Number of subjects: 1775
Study 17367093 — intervention group
Group type: EXPERIMENTAL
Intervention: AVINZA (morphine sulfate extended-release capsules)
Number of subjects: 266
Study 17367093 — intervention group
Group type: COMPARATOR
Intervention: OxyContin (oxycodone hydrochloride controlled-release tablets)
Number of subjects: 266
Study 14644065 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (200 mg, intramuscular injection)
Number of subjects: 17
Study 14644065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 11555829 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose free tissue (AFT) modeled as a nonlinear function of body weight.
Number of subjects: 273
Study 11555829 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal AFT determined by both sex and height.
Number of subjects: 273
Study 11555829 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear model for AFT and body weight relationship.
Number of subjects: 273
Study 9692412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 31
Study 9692412 — intervention group
Group type: COMPARATOR
Intervention: Dihydralazine
Number of subjects: 31
Study 7922932 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic intervention by a geriatric internist or psychiatrist and follow-up by a liaison nurse
Number of subjects: 88
Study 7922932 — intervention group
Group type: COMPARATOR
Intervention: Regular medical care (Control)
Number of subjects: 88
Study 7922932 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic intervention
Number of subjects: 88
Study 2468862 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nitrendipine (sublingually)
Number of subjects: 45
Study 2468862 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine (sublingually)
Number of subjects: 45
Study 2468862 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg clonidine (intravenously)
Number of subjects: 45
Study 30554386 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump rope exercise program (EX)
Number of subjects: 40
Study 30554386 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 40
Study 27832384 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiroxostat 160 mg/day
Number of subjects: 157
Study 27832384 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiroxostat 120 mg/day
Number of subjects: 157
Study 27832384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 27832384 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol 200 mg/day
Number of subjects: 157
Study 25963425 — intervention group
Group type: EXPERIMENTAL
Intervention: SOX plus bevacizumab
Number of subjects: 0
Study 25963425 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 plus bevacizumab
Number of subjects: 0
Study 24117062 — intervention group
Group type: EXPERIMENTAL
Intervention: IRT‐TCM (n = 46)
Number of subjects: 69
Study 24117062 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation techniques (n = 23)
Number of subjects: 69
Study 22141217 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block with 0.1% bupivacaine at a rate of 10 mL/h
Number of subjects: 40
Study 22141217 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural analgesia with 0.1% bupivacaine in continuous infusion at a rate of 8 mL/h
Number of subjects: 40
Study 18038208 — intervention group
Group type: EXPERIMENTAL
Intervention: PTVE (2-octyl cyanoacrylate)
Number of subjects: 102
Study 18038208 — intervention group
Group type: COMPARATOR
Intervention: EVL (endoscopic band ligation)
Number of subjects: 102
Study 16839319 — intervention group
Group type: EXPERIMENTAL
Intervention: Bremelanotide (20 mg, single intranasal dose)
Number of subjects: 18
Study 16839319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12571655 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g American ginseng (AG)
Number of subjects: 12
Study 12571655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10636260 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg
Number of subjects: 80
Study 10636260 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg
Number of subjects: 80
Study 10636260 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 80
Study 10636260 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg
Number of subjects: 80
Study 9374924 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive strength training for 6 months
Number of subjects: 39
Study 9374924 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining after strength training
Number of subjects: 39
Study 9374924 — intervention group
Group type: COMPARATOR
Intervention: Habitual physical activities (Control group)
Number of subjects: 39
Study 1608219 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipostabil treatment
Number of subjects: 23
Study 1608219 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 23
Study 3910730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime alone
Number of subjects: 50
Study 3910730 — intervention group
Group type: COMPARATOR
Intervention: Combination of piperacillin, netilmicin and cefotaxime
Number of subjects: 50
Study 30452747 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiologist-guided Internet-based cognitive behavioral therapy (iCBT) for tinnitus
Number of subjects: 104
Study 28950859 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip arthroscopy
Number of subjects: 140
Study 28950859 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy-led non-surgical management (Personalised Hip Therapy - PHT)
Number of subjects: 140
Study 25669177 — intervention group
Group type: EXPERIMENTAL
Intervention: Early adenotonsillectomy (eAT)
Number of subjects: 464
Study 25669177 — intervention group
Group type: COMPARATOR
Intervention: Watchful Waiting with Supportive Care (WWSC)
Number of subjects: 464
Study 25669177 — intervention group
Group type: EXPERIMENTAL
Intervention: eAT
Number of subjects: 464
Study 23303043 — intervention group
Group type: EXPERIMENTAL
Intervention: TC-5619 (1 mg day 1 to week 4, 5 mg week 4 to 8, and 25 mg week 8 to 12)
Number of subjects: 185
Study 23303043 — intervention group
Group type: EXPERIMENTAL
Intervention: TC-5619
Number of subjects: 185
Study 23303043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 21502757 — intervention group
Group type: EXPERIMENTAL
Intervention: ER‐DP plus ASA
Number of subjects: 1294
Study 21502757 — intervention group
Group type: COMPARATOR
Intervention: ASA
Number of subjects: 1294
Study 19105416 — intervention group
Group type: EXPERIMENTAL
Intervention: Velcade therapy
Number of subjects: 36
Study 16406171 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of split, trivalent influenza vaccine
Number of subjects: 720
Study 16406171 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection of split, trivalent influenza vaccine
Number of subjects: 720
Study 16406171 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of split, trivalent influenza vaccine (females)
Number of subjects: 720
Study 16406171 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection of split, trivalent influenza vaccine (females)
Number of subjects: 720
Study 15592191 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (0.74 mg/kg) sestamibi imaging
Number of subjects: 14
Study 15592191 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary Doppler
Number of subjects: 14
Study 15592191 — intervention group
Group type: EXPERIMENTAL
Intervention: Sestamibi imaging
Number of subjects: 14
Study 15592191 — intervention group
Group type: EXPERIMENTAL
Intervention: Sestamibi imaging and intracoronary Doppler
Number of subjects: 14
Study 11405162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multidisciplinary training & treatment course (ISBP)
Number of subjects: 51
Study 11405162 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 9262208 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary textured background
Number of subjects: 0
Study 9262208 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving textured background (opposite direction to target)
Number of subjects: 0
Study 9262208 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving textured background (same direction to target)
Number of subjects: 0
Study 9262208 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-field stationary backgrounds
Number of subjects: 0
Study 9262208 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-field moving background (opposite direction to target)
Number of subjects: 0
Study 9262208 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-field moving background (same direction to target)
Number of subjects: 0
Study 9262208 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-field backgrounds
Number of subjects: 0
Study 8499536 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal dietary counselling with a standard diet and fortnightly appointments
Number of subjects: 64
Study 8499536 — intervention group
Group type: COMPARATOR
Intervention: Control group with standard diet explanation and appointments at 2 and 4 months
Number of subjects: 64
Study 3691273 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cisapride 10 mg
Number of subjects: 0
Study 3691273 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cisapride 20 mg
Number of subjects: 0
Study 3691273 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cisapride (5 mg, 10 mg)
Number of subjects: 0
Study 3691273 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cisapride
Number of subjects: 0
Study 3691273 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cisapride
Number of subjects: 0
Study 3691273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30067631 — intervention group
Group type: EXPERIMENTAL
Intervention: Im-Bessel correlated beam generated via coherent modes
Number of subjects: 0
Study 30067631 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 27694590 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic alignment (KA)
Number of subjects: 71
Study 27694590 — intervention group
Group type: COMPARATOR
Intervention: Mechanical alignment (MA)
Number of subjects: 71
Study 24211316 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) 1200mg/day
Number of subjects: 24
Study 24211316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 22261836 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoendoscopic rendezvous (LERV) technique
Number of subjects: 100
Study 22261836 — intervention group
Group type: COMPARATOR
Intervention: 2-stage approach (preoperative ERCP followed by laparoscopic cholecystectomy)
Number of subjects: 100
Study 20040335 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) at a dose of 2 ‐ 3.5 g/m(2)
Number of subjects: 118
Study 18344711 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk models specific to ethnicity, gender, and Apolipoprotein E genotype developed for the trial.
Number of subjects: 0
Study 18344711 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk assessment protocols sensitive to implications of genetic testing for multiple ethnic groups.
Number of subjects: 0
Study 15971275 — intervention group
Group type: EXPERIMENTAL
Intervention: NicQb vaccine
Number of subjects: 32
Study 11208501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine treatment (2.1 mg/kg b.w. administered in 7 cycles for 12 months)
Number of subjects: 34
Study 11208501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine treatment
Number of subjects: 34
Study 11208501 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 34
Study 9042823 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (5 x 500 U epoetin beta/kg body weight intravenously over a 14-day period before surgery)
Number of subjects: 0
Study 9042823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9508938 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gluconate dentifrice
Number of subjects: 156
Study 9508938 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 156
Study 9508938 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentifrice
Number of subjects: 156
Study 3234245 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (0, 1.5, 3 and 6 mg)
Number of subjects: 14
Study 3234245 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0, 10, 20 and 40 mg)
Number of subjects: 14
Study 29536782 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg of oxycodone (Group O)
Number of subjects: 162
Study 29536782 — intervention group
Group type: COMPARATOR
Intervention: 1 µg/kg of fentanyl (Group F)
Number of subjects: 162
Study 29536782 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group S)
Number of subjects: 162
Study 27334434 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (233 mg zinc gluconate containing 30 mg zinc) for 6 weeks
Number of subjects: 40
Study 27334434 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 40
Study 27334434 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (233 mg zinc gluconate)
Number of subjects: 40
Study 23269105 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (flexible-dose, target dose 200 mg/d)
Number of subjects: 38
Study 23269105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 21655893 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior cruciate‐sacrificing mobile‐bearing prosthesis
Number of subjects: 107
Study 21655893 — intervention group
Group type: COMPARATOR
Intervention: Posterior‐stabilized mobile‐bearing prosthesis
Number of subjects: 107
Study 19454920 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused therapy for adolescents (FFT-A)
Number of subjects: 58
Study 19454920 — intervention group
Group type: COMPARATOR
Intervention: Enhanced care (EC)
Number of subjects: 58
Study 17436601 — intervention group
Group type: COMPARATOR
Intervention: 200 IU/day rFSH
Number of subjects: 0
Study 17436601 — intervention group
Group type: COMPARATOR
Intervention: Low-dose step-up OI protocol with weekly increments of 25 IU/day rFSH
Number of subjects: 0
Study 17436601 — intervention group
Group type: COMPARATOR
Intervention: 150 IU/day rFSH
Number of subjects: 0
Study 15545098 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox injections (18 units per area) with ablative laser resurfacing
Number of subjects: 33
Study 15545098 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo injections with ablative laser resurfacing
Number of subjects: 33
Study 11384635 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg recombinant hCG (rhCG)
Number of subjects: 198
Study 11384635 — intervention group
Group type: COMPARATOR
Intervention: 5,000 IU urinary hCG (uhCG)
Number of subjects: 198
Study 9141121 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthesis with 907 grammes mass added
Number of subjects: 20
Study 9141121 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthesis with 454 grammes mass added
Number of subjects: 20
Study 9141121 — intervention group
Group type: COMPARATOR
Intervention: Prosthesis without mass added
Number of subjects: 20
Study 9141121 — intervention group
Group type: COMPARATOR
Intervention: Non-amputee control with mass added
Number of subjects: 20
Study 7526065 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg
Number of subjects: 75
Study 7526065 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 20 mg
Number of subjects: 75
Study 7526065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 3415888 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl by patient controlled analgesia (PCA)
Number of subjects: 16
Study 3415888 — intervention group
Group type: COMPARATOR
Intervention: Saline by infusion pump plus morphine 10 mg/70 kg s.c. (Control)
Number of subjects: 16
Study 29047215 — intervention group
Group type: EXPERIMENTAL
Intervention: 103 mg of p-synephrine (S)
Number of subjects: 16
Study 29047215 — intervention group
Group type: EXPERIMENTAL
Intervention: 233 mg of caffeine + 104 mg of p-synephrine (LC + S)
Number of subjects: 16
Study 29047215 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg of caffeine (LC)
Number of subjects: 16
Study 29047215 — intervention group
Group type: EXPERIMENTAL
Intervention: 337 mg of caffeine + 46 mg of p-synephrine (HC + S)
Number of subjects: 16
Study 29047215 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg of caffeine (HC)
Number of subjects: 16
Study 29047215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 28198729 — intervention group
Group type: EXPERIMENTAL
Intervention: Land exercise (107 women)
Number of subjects: 568
Study 28198729 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exercise (49 women)
Number of subjects: 568
Study 28198729 — intervention group
Group type: EXPERIMENTAL
Intervention: Land + water exercise (101 women)
Number of subjects: 568
Study 28198729 — intervention group
Group type: COMPARATOR
Intervention: Control group (311 women)
Number of subjects: 568
Study 26755464 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Coping Skills Training (CST) and Pharmacotherapy (Ph)
Number of subjects: 35
Study 26755464 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy (Ph) alone
Number of subjects: 35
Study 23338669 — intervention group
Group type: EXPERIMENTAL
Intervention: CID (Child Incentive Delay)
Number of subjects: 30
Study 23338669 — intervention group
Group type: COMPARATOR
Intervention: MID (Monetary Incentive Delay)
Number of subjects: 30
Study 21235403 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions to improve ART adherence
Number of subjects: 204
Study 21235403 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 204
Study 18447091 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing Awareness Meditation (BAM), 10-minute sessions daily for three months
Number of subjects: 66
Study 18447091 — intervention group
Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 66
Study 22686429 — intervention group
Group type: EXPERIMENTAL
Intervention: DEH (dehydration with no fluid intake)
Number of subjects: 13
Study 22686429 — intervention group
Group type: COMPARATOR
Intervention: CON (rehydration with fluid intake)
Number of subjects: 13
Study 16286955 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine treatment
Number of subjects: 70
Study 16286955 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 70
Study 14579656 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethindene maleate (DMM) nasal spray for 2 weeks
Number of subjects: 157
Study 14579656 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 157
Study 14579656 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethindene maleate (DMM) nasal spray
Number of subjects: 157
Study 14579656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 9686728 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin treatment for Ureaplasma urealyticum colonized infants.
Number of subjects: 124
Study 9686728 — intervention group
Group type: COMPARATOR
Intervention: Noncolonized infants (control group).
Number of subjects: 124
Study 7649339 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg nicergoline, orally, daily for 6 months
Number of subjects: 57
Study 7649339 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8-6 mg co-dergocrine mesylate, orally or intramuscularly, daily for 6 months
Number of subjects: 57